BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in Its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance


6/22/2011 9:31:16 AM

LOS ANGELES, CA--(Marketwire - June 21, 2011) -

Ritter Pharmaceuticals, Inc. (Ritter), a pharmaceutical company with a focus on digestive diseases, announced today that clinical investigators have enrolled the first patient in its randomized, double-blind, placebo-controlled Phase 2 study of RP-G28 in patients with symptoms associated with lactose intolerance. The study, which is being conducted by investigators in clinical sites in Honolulu, Hawaii and Dallas, Texas, is expected to enroll approximately 80 patients. The objectives of the study are to evaluate the efficacy, safety and tolerability of RP-G28 in treating the symptoms of lactose intolerance. Ritter expects initial study results in the first quarter of 2012.

RP-G28 has the potential to become the first prescription drug approved for treating the symptoms of lactose intolerance, which affects more than 80 million people in the United States and 4.3 billion people worldwide.

"Based on the promising results from our development work, we are excited to initiate this clinical study which is designed to more fully characterize the therapeutic potential of RP-G28 in treating lactose intolerance," said Ritter's President & CEO Andrew Ritter. "This is an important next step toward making RP-G28 available to lactose intolerance sufferers around the world."

For additional information, including a list of the Research Centers conducting Ritter's Phase 2 Clinical Study in Honolulu, Hawaii and Dallas, Texas, visit www.ClinicalTrials.gov

About Lactose Intolerance

Lactose intolerance is the inability to digest dairy products, such as milk, ice cream, cheese and pizza. Symptoms typically occur after eating foods with lactose and frequently cause problems in the digestive or gastrointestinal (GI) system.

About Ritter Pharmaceuticals, Inc.

Ritter is committed to the discovery, development and commercialization of innovative therapies for GI disorders. The Company's scientific platform of GI physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of disorders, including lactose intolerance, irritable bowel syndrome, inflammatory bowel disease, and traveler's diarrhea. Ritter's mission is to help individuals live a healthier and happier lifestyle through improved digestion and overall well being.


Contact:

Justin Chandler
Director of Operations
Ritter Pharmaceuticals, Inc.
(310) 203-1000
http://www.RitterPharma.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES